Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy
Dana V. Rizk, Nicolas Maillard, Bruce A. Julian, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 133

Showing 1-25 of 133 citing articles:

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue
Laura Connelly‐Smith, Caroline R. Alquist, Nicole A. Aqui, et al.
Journal of Clinical Apheresis (2023) Vol. 38, Iss. 2, pp. 77-278
Closed Access | Times Cited: 284
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy
Hong Zhang, Dana V. Rizk, Vlado Perkovic, et al.
Kidney International (2023) Vol. 105, Iss. 1, pp. 189-199
Open Access | Times Cited: 55
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
Vlado Perkovic, Jonathan Barratt, Brad H. Rovin, et al.
New England Journal of Medicine (2024)
Closed Access | Times Cited: 20
Podocyte-targeted therapies — progress and future directions
Kristin Meliambro, John Cijiang He, Kirk N. Campbell
Nature Reviews Nephrology (2024) Vol. 20, Iss. 10, pp. 643-658
Closed Access | Times Cited: 16
Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy
Richard A. Lafayette, Brad H. Rovin, Heather N. Reich, et al.
Kidney International Reports (2020) Vol. 5, Iss. 11, pp. 2032-2041
Open Access | Times Cited: 122
Complement activation in IgA nephropathy
Nicholas Medjeral‐Thomas, H. Terence Cook, Matthew C. Pickering
Seminars in Immunopathology (2021) Vol. 43, Iss. 5, pp. 679-690
Open Access | Times Cited: 75
Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway
Jonathan Barratt, Ilene Weitz
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 73
Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria
Jonathan Barratt, James A. Tumlin, Yusuke Suzuki, et al.
Kidney International Reports (2022) Vol. 7, Iss. 8, pp. 1831-1841
Open Access | Times Cited: 66
Deposition of the Membrane Attack Complex in Healthy and Diseased Human Kidneys
Jacob J.E. Koopman, Mieke F. van Essen, Helmut G. Rennke, et al.
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 61
Pathogenesis of IgA Nephropathy: Current Understanding and Implications for Development of Disease-Specific Treatment
Barbora Knoppová, Colin Reily, R. Glenn King, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 19, pp. 4501-4501
Open Access | Times Cited: 59
Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial
Andrew S. Bomback, David Kavanagh, Marina Vivarelli, et al.
Kidney International Reports (2022) Vol. 7, Iss. 10, pp. 2150-2159
Open Access | Times Cited: 45
Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study
Dana V. Rizk, Brad H. Rovin, Hong Zhang, et al.
Kidney International Reports (2023) Vol. 8, Iss. 5, pp. 968-979
Open Access | Times Cited: 31
The Treatment of Primary IgA Nephropathy: Change, Change, Change
Dawn J. Caster, Richard A. Lafayette
American Journal of Kidney Diseases (2023) Vol. 83, Iss. 2, pp. 229-240
Closed Access | Times Cited: 24
Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgG immune complexes in a mouse model of IgA nephropathy
Colin Reily, Zina Moldoveanu, Tiziano Pramparo, et al.
AJP Renal Physiology (2024) Vol. 326, Iss. 5, pp. F862-F875
Open Access | Times Cited: 10
Drugs in Development to Treat IgA Nephropathy
Lucia Del Vecchio, Marco Allinovi, Stefania Comolli, et al.
Drugs (2024) Vol. 84, Iss. 5, pp. 503-525
Closed Access | Times Cited: 9
Complement Inhibition Therapy in IgA Nephropathy: Total or Selective Inhibition?
Zhiyong Zhu, Chengcai Zhang, Hongyun Wang, et al.
Journal of the American Society of Nephrology (2025)
Closed Access | Times Cited: 1
The Role of IgA in the Pathogenesis of IgA Nephropathy
Martina Perše, Željka Večerić‐Haler
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 24, pp. 6199-6199
Open Access | Times Cited: 69
A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy
R. D. Wright, Fariba Bannerman, Michael W. Beresford, et al.
BMC Nephrology (2020) Vol. 21, Iss. 1
Open Access | Times Cited: 65
Structure of the C1r–C1s interaction of the C1 complex of complement activation
Jamal O. M. Almitairi, Umakhanth Venkatraman Girija, Christopher M. Furze, et al.
Proceedings of the National Academy of Sciences (2018) Vol. 115, Iss. 4, pp. 768-773
Open Access | Times Cited: 60
IgA vasculitis with nephritis: update of pathogenesis with clinical implications
Margaret Hastings, Dana V. Rizk, Krzysztof Kiryluk, et al.
Pediatric Nephrology (2021) Vol. 37, Iss. 4, pp. 719-733
Open Access | Times Cited: 52
An Update on the Current State of Management and Clinical Trials for IgA Nephropathy
Chee Kay Cheung, Arun Rajasekaran, Jonathan Barratt, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 11, pp. 2493-2493
Open Access | Times Cited: 52
Inflammatory and Oxidative Pathways Are New Drug Targets in Multiple Episode Schizophrenia and Leaky Gut, Klebsiella pneumoniae, and C1q Immune Complexes Are Additional Drug Targets in First Episode Schizophrenia
Michaël Maes, Aristo Vojdani, Sunee Sirivichayakul, et al.
Molecular Neurobiology (2021)
Closed Access | Times Cited: 47
IgA Vasculitis and IgA Nephropathy: Same Disease?
Évangéline Pillebout
Journal of Clinical Medicine (2021) Vol. 10, Iss. 11, pp. 2310-2310
Open Access | Times Cited: 44
Targeting complement in IgA nephropathy
Fernando Caravaca‐Fontán, Eduardo Gutiérrez, Ángel Sevillano, et al.
Clinical Kidney Journal (2023) Vol. 16, Iss. Supplement_2, pp. ii28-ii39
Open Access | Times Cited: 20
Diagnostic and Management Strategies of IgA Vasculitis Nephritis/Henoch-Schönlein Purpura Nephritis in Pediatric Patients: Current Perspectives
Mario Šestan, Marija Jelušić
Pediatric Health Medicine and Therapeutics (2023) Vol. Volume 14, pp. 89-98
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top